Company Performance - Pacific Biosciences of California (PACB) closed at $2.26, reflecting a -4.64% change from the previous day, underperforming the S&P 500's daily loss of 0.43% [1] - Over the past month, PACB shares have gained 26.74%, while the Medical sector has lost 2.36% and the S&P 500 has gained 0.89% [1] Earnings Estimates - The company is expected to release its earnings on February 12, 2026, with projected earnings per share (EPS) of -$0.19, indicating a 5% increase from the same quarter last year [2] - Full-year Zacks Consensus Estimates predict earnings of -$1.89 per share and revenue of $0 million, representing year-over-year changes of -127.71% and 0%, respectively [3] Analyst Insights - Recent changes to analyst estimates for Pacific Biosciences should be monitored, as positive revisions are often seen as a good sign for business outlook [3] - The Zacks Rank system, which includes estimate changes, currently ranks Pacific Biosciences at 3 (Hold), with no changes in the Zacks Consensus EPS estimate over the past month [5] Industry Context - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 88, placing it in the top 36% of over 250 industries [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

Core Viewpoint - Hologic reported quarterly earnings of $1.04 per share, missing the Zacks Consensus Estimate of $1.09 per share, representing an earnings surprise of -4.46% [1]. Financial Performance - The company posted revenues of $1.05 billion for the quarter ended December 2025, which was below the Zacks Consensus Estimate by 2.14%, compared to $1.02 billion in the same quarter last year [2]. - Over the last four quarters, Hologic has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2]. Stock Performance - Hologic shares have increased by approximately 0.8% since the beginning of the year, while the S&P 500 has gained 1.9% [3]. - The current Zacks Rank for Hologic is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6]. Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.09 on revenues of $1.05 billion, and for the current fiscal year, it is $4.51 on revenues of $4.28 billion [7]. - The trend of earnings estimate revisions for Hologic was mixed ahead of the earnings release, which could change following the recent report [6]. Industry Context - The Medical - Instruments industry, to which Hologic belongs, is currently in the top 38% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8].

Thermo Fisher Scientific (TMO) came out with quarterly earnings of $6.57 per share, beating the Zacks Consensus Estimate of $6.43 per share. This compares to earnings of $6.1 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.13%. A quarter ago, it was expected that this maker of scientific instrument and laboratory supplies would post earnings of $5.5 per share when it actually produced earnings of $5.79, delivering a surpris ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Veracyte (VCYT) , which belongs to the Zacks Medical - Instruments industry.When looking at the last two reports, this molecular diagnostic company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 50.66%, on average, in the last two quarters.For the last reported quarter, Veracyte came out with earnings of $0. ...

Company Performance - Pacific Biosciences of California (PACB) closed at $2.58, reflecting a decrease of -3.37% from the previous day's closing price, underperforming the S&P 500's daily gain of 0.03% [1] - Over the past month, PACB shares have increased by 42.02%, outperforming the Medical sector's slight loss of -0.01% and the S&P 500's gain of 0.6% [1] Earnings Expectations - Analysts anticipate that Pacific Biosciences will report earnings of -$0.19 per share, indicating a year-over-year growth of 5% [2] - For the entire fiscal year, the Zacks Consensus Estimates project earnings of -$1.89 per share and revenue of $0 million, representing changes of -127.71% and 0% from the prior year, respectively [2] Analyst Estimates - Recent changes to analyst estimates for Pacific Biosciences reflect shifting short-term business dynamics, with positive revisions indicating optimism about the business outlook [3] - The Zacks Rank system, which incorporates these estimate changes, provides an actionable rating system for investors [4] Zacks Rank and Industry Performance - The Zacks Rank system ranges from 1 (Strong Buy) to 5 (Strong Sell), with stocks rated 1 delivering an average annual return of +25% since 1988 [5] - Pacific Biosciences currently holds a Zacks Rank of 3 (Hold), with the consensus EPS projection remaining stagnant over the past 30 days [5] - The Medical - Instruments industry, part of the Medical sector, has a Zacks Industry Rank of 92, placing it in the top 38% of all industries [6]

Core Viewpoint - Penumbra's stock price surged 11.8% to close at $350.49, driven by strong trading volume and positive investor sentiment following the announcement of preliminary financial results for Q4 and full year 2025 [1][2]. Financial Performance - Q4 2025 revenue is projected to be between $383.0 million and $384.8 million, indicating a year-over-year growth of approximately 21.4% to 22.0% [2]. - Full year revenue for 2025 is expected to range from $1,401.3 million to $1,403.1 million, reflecting a year-over-year growth of about 17.3% to 17.5% [2]. - The upcoming quarterly earnings are anticipated to be $1.12 per share, representing a year-over-year increase of 15.5%, with revenues expected at $362.5 million, up 14.9% from the previous year [3]. Market Sentiment - Investor optimism is bolstered by Boston Scientific's agreement to acquire Penumbra at $374 per share, contributing to the stock's recent price increase [2]. - The consensus EPS estimate for Penumbra has been revised slightly higher over the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4]. Industry Context - Penumbra operates within the Zacks Medical - Instruments industry, where another company, Masimo, has shown a modest increase of 1.1% in its stock price [4]. - Masimo's EPS estimate has remained unchanged at $1.4, reflecting a year-over-year decline of 22.2%, and it currently holds a Zacks Rank of 4 (Sell) [5].

Core Insights - The article compares Coloplast A/S Sponsored ADR (CLPBY) and Penumbra (PEN) to determine which stock offers better value for investors [1] Valuation Metrics - CLPBY has a forward P/E ratio of 21.75, significantly lower than PEN's forward P/E of 63.30 [5] - CLPBY's PEG ratio is 0.84, indicating a more favorable earnings growth outlook compared to PEN's PEG ratio of 1.97 [5] - CLPBY's P/B ratio stands at 8.32, while PEN's P/B ratio is higher at 9.29 [6] Zacks Rank - CLPBY currently holds a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, whereas PEN has a Zacks Rank of 3 (Hold) [3] Value Grades - Based on various valuation metrics, CLPBY has a Value grade of B, while PEN has a Value grade of D, suggesting that CLPBY is the superior value option at this time [6]

Investors interested in Medical - Instruments stocks are likely familiar with Hologic (HOLX) and SONOVA HOLDING (SONVY) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Score ...

Core Viewpoint - Intuitive Surgical, Inc. is set to report earnings that indicate modest growth, with analysts showing a positive outlook based on recent estimate revisions Financial Performance - In the upcoming earnings disclosure, Intuitive Surgical, Inc. is projected to report earnings of $2.25 per share, reflecting a year-over-year growth of 1.81% [2] - The consensus estimate for revenue is $2.72 billion, indicating a 12.59% increase from the same quarter last year [2] - For the entire fiscal year, earnings are projected at $8.65 per share and revenue at $9.92 billion, representing changes of +17.85% and +18.72% respectively from the prior year [3] Analyst Estimates - Recent adjustments to analyst estimates for Intuitive Surgical, Inc. suggest a positive sentiment regarding the company's business operations and profit generation capabilities [4] - The Zacks Consensus EPS estimate has seen a 0.58% increase over the last 30 days, and the company currently holds a Zacks Rank of 2 (Buy) [6] Valuation Metrics - Intuitive Surgical, Inc. has a Forward P/E ratio of 66.19, which is significantly higher than the industry average of 25.28 [7] - The company has a PEG ratio of 4.22, compared to the Medical - Instruments industry's average PEG ratio of 2.28 [8] Industry Context - The Medical - Instruments industry, which includes Intuitive Surgical, currently has a Zacks Industry Rank of 162, placing it in the bottom 35% of over 250 industries [8] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks, with top-rated industries outperforming the bottom half by a factor of 2 to 1 [9]

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Idexx Laboratories (IDXX) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Idexx Laboratories is one of 946 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 differe ...